Aug. 29 at 3:28 PM
$BNTX investors following personalised cancer vaccines should take a look at
$NWBO . DCVax-L takes a completely different approach from mRNA, using a patient's own tumour material to create a personalised dendritic-cell vaccine. The Phase 3 trial has already reported results and the programme is now at the regulatory stage. Interesting space to compare.